Biblio

Author Title [ Type

] Year

Filters: Author is Schroers, Roland [Clear All Filters]

Journal Article

Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase . Lancet Haematol. 2022;9(11):e810-e821.

Hagenkötter M, Mika T, Ladigan-Badura S, Schork K, Eisenacher M, Schroers R, Baraniskin A. Comparison of peripheral blood automated hematopoietic progenitor cell count and flow cytometric CD34+ cell count. J Clin Apher. 2024;39(3):e22114.

Mika T, Baraniskin A, Ladigan S, Wulf G, Dierks S, Haase D, Schork K, Turewicz M, Eisenacher M, Schmiegel W, et al. Digital droplet PCR-based chimerism analysis for monitoring of hematopoietic engraftment after allogeneic stem cell transplantation. Int J Lab Hematol. 2019.

Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, et al. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Lancet Haematol. 2024;11(2):e101-e113.

Bethge WAndreas, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EMaria, Wulf GG, Marks R, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022.

Nilius-Eliliwi V, Treiber H, Seidel S, Vangala DB, Schroers R. High-dose chemotherapy and autologous stem cell transplantation in primary lymphomatoid granulomatosis of the central nervous system. J Cancer Res Clin Oncol. 2022.

Derigs P, Bethge WA, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, et al. Long-Term Survivors After Failure of CAR-T Cell Therapy for Large B-Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A GLA/DRST Analysis. Transplant Cell Ther. 2023.

Penack O, Dreger P, Ajib S, Ayuk F, Baermann B-N, Bug G, Kriege O, Jentzsch M, Kobbe G, Koenecke C, et al. Management of Patients undergoing CAR-T cell therapy in Germany. Oncol Res Treat. 2024.

Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H-G, Arseniev L, Beier R, Beutel G, Cario G, et al. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. J Clin Invest. 2023.

Habringer S, Demel UM, Fietz A-K, Lammer F, Schroers R, Hofer S, Bairey O, Braess J, Meier-Stiegen ASofia, Stuhlmann R, et al. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma. Eur J Cancer. 2023;196:113436.

Treiber H, Nilius-Eliliwi V, Seifert N, Vangala D, Wang M, Seidel S, Mika T, Marschner D, Zeremski V, Wurm-Kuczera R, et al. Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 Patients. Hemasphere. 2023;7(8):e926.